Skip to content
DataLookout
Menu

NCT07934264

[18F]ZDG2 First-in-Human PET Imaging in PAH

StatusNot Yet Recruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria changed
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Incidence and severity of adverse events
Timeframe: From enrolment to the final follow up visit, 3-7 days after the last dose.
Changes in blood pressure from baseline
Timeframe: From enrolment to the final follow up visit, 3-7 days after the last dose.
Changes in heart rate from baseline
Timeframe: From enrolment to the final follow up visit, 3-7 days after the last dose.
Changes in oxygen saturation from baseline
Timeframe: From enrolment to the final follow up visit, 3-7 days after the last dose.
Changes in temperature from baseline
Timeframe: From enrolment to the final follow up visit, 3-7 days after the last dose.
Standardized uptake values in major organs
Timeframe: From tracer administration to the final scan at 180 minutes post administration
Number of participants with abnormal results in hematology assessments
Timeframe: From enrolment to the final follow up visit, 3-7 days after the last dose.
Number of participants with abnormal results in chemistry laboratory assessments
Timeframe: From enrolment to the final follow up visit, 3-7 days after the last dose.
Number of participants with abnormal results in coagulation laboratory assessments
Timeframe: From enrolment to the final follow up visit, 3-7 days after the last dose.
Number of participants with abnormal results in urinalysis laboratory assessments
Timeframe: From enrolment to the final follow up visit, 3-7 days after the last dose.
Number of participants with abnormal results in NTproBNP laboratory assessments
Timeframe: From enrolment to the final follow up visit, 3-7 days after the last dose.
Number of participants with abnormal results in HgbA1c laboratory assessments
Timeframe: From enrolment to the final follow up visit, 3-7 days after the last dose.
Time-activity curves for major organs including lungs and heart
Timeframe: From tracer administration to the final scan at 180 minutes post administration
Identification of excretory pathways
Timeframe: From tracer administration to the final scan at 180 minutes post administration
Radiation Dosimetry
Timeframe: From tracer administration to the final scan at 180 minutes post administration.
Plasma concentration-time profile
Timeframe: From tracer administration to the final scan at 180 minutes post administration
Parent fraction analysis
Timeframe: From tracer administration to the final scan at 180 minutes post administration
Plasma free fraction determination
Timeframe: From tracer administration to the final scan at 180 minutes post administration

Secondary (7)

VEGFR Quantification
Mean pulmonary artery pressure
Pulmonary vascular resistance
Cardiac output
Cardiac index
Show 2 moreShow less
WHO functional class
Highest pulmonary artery-to-background ratio

Arms and interventions

PAH PatientsExperimental

Patients diagnosed with PAH will receive the tracer. A subset (10/12) will participate in reproducibility testing.

Healthy VolunteersExperimental

Healthy volunteers will receive the tracer.

Drugs: [18F]ZDG2- Single Dose

Sites

1 site in 1 country

  • Houston Methodist Research InstituteHouston, Texas, United States